Subscribe
shutterstock_1335829340_manuel-esteban
manuelesteban / Shutterstock.com
8 April 2019Americas

Sun Pharma takes Pfizer to court over Lyrica

India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica (pregabalin).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer and Sun settle Bosulif dispute
6 November 2019   Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Americas
Pfizer expects $1.9bn loss due to patent expirations
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Pfizer and Sun settle Bosulif dispute
6 November 2019   Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Americas
Pfizer expects $1.9bn loss due to patent expirations
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

More on this story

Americas
Pfizer and Sun settle Bosulif dispute
6 November 2019   Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Americas
Pfizer expects $1.9bn loss due to patent expirations
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims